In addition, Gullà and colleagues showed that upregulation of protein arginine methyltransferase 5 (PRMT5), an enzyme involved in growth and survival pathways that promote tumorigenesis, was closely associated with decreased progression-free survival (PFS) and overall survival (OS) in immunopurified CD138+ cells, suggesting the oncogenic role and prognostic significance of PRMT5 in MM pathogenesis (138). The gene discussed is PRMT5; the disease is Miyoshi myopathy.